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SUMMARY
The phenomenon of protein misfolding and aggregation is associated with a wide range of neurode-
generative conditions that cause progressive loss of function in specific regions of the human brain. To
understand the causes of the selective cell and tissue vulnerability to the formation of these deposits,
we analyzed the ability of different cell and tissue types to respond, in the absence of disease, to the
presence of high levels of aggregation-prone proteins. By performing a transcriptional analysis, we
found that the protein homeostasis system that regulates protein aggregation is weaker in neurons
than in other cell types and in brain tissues than in other body tissues. These results suggest that
the intrinsic level of regulation of protein aggregation in the healthy state is correlated with the selec-
tive vulnerability of cells and tissues to protein misfolding diseases.
INTRODUCTION
Neurodegenerative disorders are multifactorial conditions characterized by extensive neuronal dysfunc-
tion associated with the misfolding and aggregation of a specific set of proteins that form aberrant de-
posits, including amyloid plaques and neurofibrillary tangles in Alzheimer’s disease and Lewy bodies in Par-
kinson’s disease (De Strooper and Karran, 2016; Eisenberg and Jucker, 2012; Holtzman et al., 2011; Selkoe
and Hardy, 2016; Knowles et al., 2014). Increasing evidence also indicates that protein aggregation is a
widespread phenomenon, as hundreds of proteins unrelated in sequence or structure have been found
to form insoluble assemblies under conditions of stress, aging, or disease (Chapman et al., 2006; Ciryam
et al., 2015, 2017; David et al., 2010; Gidalevitz et al., 2006; Tartaglia et al., 2007; Walther et al., 2015).
To rationalize these observations, it has recently been reported that a large fraction of the proteome is
inherently metastable against aggregation within the cellular environment (Ciryam et al., 2013, 2015,
2016, 2017; Yerbury et al., 2019). Proteins are metastable in their native states when their cellular concen-
trations exceed their intrinsic solubilities (Tartaglia et al., 2007; Vecchi et al., 2020). Indeed, proteins that co-
aggregate in plaques, tangles, and Lewy bodies have been found to be highly metastable against aggre-
gation (Ciryam et al., 2013), and biochemical pathways associated with neurodegenerative diseases,
including in particular oxidative phosphorylation, have been reported to be enriched in these proteins,
hereafter referred to as metastable proteins, thus revealing a common feature for these otherwise very
different neurodegenerative conditions (Ciryam et al., 2013). Moreover, a fraction of these metastable pro-
teins were reported to be specifically transcriptionally downregulated in Alzheimer’s disease (Ciryam et al.,
2016). This metastable subproteome associated with Alzheimer’s disease was found to be associated pri-
marily with specific components of the protein trafficking and clearance mechanisms, in particular the en-
dosomal-lysosomal and the ubiquitin-proteasome systems (Kundra et al., 2017). These results suggest that
these quality control systems are crucial for the maintenance of the cellular homeostasis of a set of meta-
stable proteins prone to aggregation in Alzheimer’s disease.
In addition, the protein quality control mechanisms, which are collectively known as the protein homeostasis
system, have been shown quite generally to become progressively impaired upon aging and in neurodegen-
erative diseases, resulting in increased accumulation of aggregated species (Balch et al., 2008; Freer et al., 2016;
Freer et al., 2019; Fu et al., 2018, 2019; Hipp et al., 2014; Knowles et al., 2014). Hence, it is crucial to maintain a
balance between the levels of aggregation-prone proteins and their associated protein homeostasis compo-
nents in order to preserve overall cellular health. Further studying these effects may therefore help answer the
question of why a large number of the diseases associatedwith protein aggregation involve the central nervous
system. Although there have been a number of studies about the vulnerability of specific brain tissues (Bero
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et al., 2011; Mattson and Magnus, 2006; Miller et al., 2013), it is still not completely clear why the brain itself is
more vulnerable to the aggregation phenomenon compared with other body tissues.
The aim of the present study is to address this question by investigating whether healthy brains are more
susceptible to the effects of protein misfolding diseases than other organs, by examining at the transcrip-
tional level the balance between the expression of aggregation-prone proteins and the efficacy of their cor-
responding protein homeostasis control system. To achieve this goal, we determined the expression levels
of metastable proteins associated with Alzheimer’s disease and their associated protein homeostasis com-
ponents across nearly 80 different healthy human tissues, including several ones from the brain. Our expec-
tation is that brain tissues, compared with those from other regions of the body, should have a higher level
of expression of the set of metastable proteins but a lower expression of the associated homeostasis com-
ponents. In this view, due to the inherent lower expression levels of the quality control components asso-
ciated with metastable proteins, certain regions of the brain would not have the ability to mount a robust
response to these highly aggregation-prone metastable proteins, suggesting an origin for the selective
vulnerability of the brain to protein misfolding diseases.
RESULTS
The Strength of the Protein Homeostasis System that Responds to Protein Aggregation Is
Proportional to Level of Gene Expression of a Metastable Subproteome
Because aggregation-prone proteins are intrinsically metastable even in the absence of disease, we studied
healthy brain tissues to identify their associated protein homeostasis components using an approach based
on coexpression network analysis (see Supplemental Information). We used a subset of these metastable pro-
teins specifically associated with Alzheimer’s disease (Ciryam et al., 2016), as our aim was to study the vulnera-
bility of different tissues to this disease. In this way, using a weighted coexpression approach (Langfelder and
Horvath, 2008), we identified the protein homeostasis components (PHC) associated with this metastable sub-
proteome (MS) (Kundraet al., 2017).We thenusedhereextensivemicroarray dataobtained for 77different types
of healthy human tissues (Su et al., 2004) to study the vulnerability of various tissues basedon the relative expres-
sion of thesegenes (Table S1).We carriedout this analysis by defining a protection factor, s, as the correlation of
the relative expression levels of theMS and its corresponding PHC. When s = 1 the response to protein aggre-
gation in a given tissue matches exactly, at the transcript level, the requirement to prevent aggregation of the
metastable proteins, whereas values below 1 indicate a lower, and possibly ineffective, response. We found
from this analysis that the brain tissues have an elevated expression of genes corresponding to the MS, but
not of their protein homeostasis counterpart, relative to other types of tissues in the body (Figure 1A). Although
in body tissues the PHC expression level grows more rapidly than that of the MS (s = 1.33), in brain tissues the
opposite is true (s = 0.88). Thus, although the protein homeostasis response in all tissues tends to be generally
proportional to the pressure toward protein aggregation, brain tissues tend tobehave differently fromother tis-
sues (Figure 1B) and have an overall weaker response.
Vulnerable Brain Tissues Have a Weaker Response to the Pressure toward Protein
Aggregation Than Non-vulnerable Ones
The greater vulnerability of brain tissues to the pressure toward protein aggregation observed above suggests
the presence of a link between the levels of regulation of protein aggregation and the development of neuro-
degenerative processes in Alzheimer disease. In order to investigate this relationship in more detail, we differ-
entiated between tissues that are vulnerable and those that are resistant to neurodegeneration in Alzheimer’s
disease, as assessed by the Braak staging (Braak and Braak, 1991).Wemapped different types of brain tissue to
the respective Braak stages as reported previously (Freer et al., 2016; Freer et al., 2019). Seven of these tissues
corresponded todifferent Braak stagespresent in themicroarray dataset used in the current study.Weanalyzed
the levels of expression of theMS and the associated PHC in these types of tissue and compared themwith the
tissues not affected in Braak stages. We found that brain tissues corresponding to Braak regions have a lower
value of s than do those of the non-Braak regions (Figure 2). These results reveal a close link between the regu-
lation of the pressure toward protein aggregation with tissue vulnerability to Alzheimer’s disease.
Neurons Have a Lower Ability to Maintain Protein Homeostasis Than Other Types of Brain
Cells
These results suggest a possibleorigin for the increased vulnerability of neurons to changes that lead toAlzheim-
er’s disease relative to other non-neuronal brain cell types. In order to verify whether or not neurons are less able
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Figure 1. The Protein Homeostasis System that Responds to Protein Aggregation Is Weaker in Brain Tissues
Compared with Other Tissues in the Human Body
(A) Comparison between the average expression of genes corresponding to the metastable subproteome (MS) and the
average expression of the genes corresponding to the associated protein homeostasis components (PHC) in 77 different
types of human tissue (Table S1). The protection factor s defines the strength of the protein homeostasis response to the
presence of metastable proteins. Brain tissues have smaller values of s (orange, s = 0.88) than other tissues of the body
(blue, s = 1.13), indicating that brain tissues have a reduced ability to protect themselves from protein aggregation
relative to other tissues.
(B) Correlation matrix of gene expression levels in different tissues, where the correlation is calculated for the genes
corresponding to the MS and their associated PHC. The intensity of the colors and the size of the circles are proportional
to the correlation coefficients. Brain tissues (first row) are only weakly correlated with other body tissues, as also illustrated
by the body image on the bottom left. The statistical significance was evaluated as explained in Methods and in Figure S1.
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than other brain cell types to regulate protein aggregation, we compared the expression of genes correspond-
ing to theMSand their associated protein homeostasis components (PHC) in neurons, astrocytes,microglia, and
oligodendrocytes, using extensive single-cell RNA sequencing data (Habib et al., 2017; Lake et al., 2016). We
found that neurons have the lowest value of the protection factor s among these cell types (Figure 3), indicating
that neurons are indeed the cell types most vulnerable to protein aggregation in the brain.
Proteins in the Oxidative Phosphorylation Pathway Have a Reduced Ability to Maintain
Protein Homeostasis in the Brain Than in Other Tissues
In order to understand inmore detail themolecular origins of the increased vulnerability of certain types of brain
cells and tissues to the effects leading to Alzheimer’s disease, we considered the ability of the cells to regulate
oxidative phosphorylation, because this is a specific process associated with metastable proteins (Ciryam et al.,
2016; Kundra et al., 2017), and more generally with neurodegenerative diseases (Lin and Beal, 2006; Rhein et al.,
2009). We divided the genes associated with the oxidative phosphorylation pathway into two parts, those that
are metastable and those that are not (Table S2). We then calculated the value of protection factor s for the
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Figure 2. Brain Tissues Vulnerable to Alzheimer’s Disease Have a
Weaker Protein Homeostasis Response to Protein Aggregation
than Non-vulnerable Brain Tissues
Brain tissues corresponding to different Braak regions have a lower
value of the protection factor s compared with that of non-Braak
regions; for comparison the protection factor of other body tissues is
also shown. ***p < 0.001.
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Figure 3. Neurons Have a Weaker Protein Homeostasis Response to Protein Aggregation than Non-neuronal
Brain Cell Types
Scatterplots depicting the expression of genes corresponding to the metastable subproteome (MS) and their associated
protein homeostasis components (PHC) in (A) neurons, (B) astrocytes, (C) microglia, and (D) oligodendrocytes. Each dot
represents an individual cell. The level of significance between different values of s is shown in Figure S2.
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oxidative phosphorylation genes and their associated PHC for both groups across all tissues. The difference in s
values between the body and brain tissues (Ds) is higher for the group of oxidative phosphorylation genes that
are metastable, whereas there is almost no difference in the values of s for non-metastable oxidative phosphor-
ylation genes. These results suggest that, even within the oxidative phosphorylation pathway, those genes that
are also metastable pose a higher risk for the brain tissues, as these are less well prepared to face the challenge
posed by the presence of these aggregation-prone proteins (Figure 4).
DISCUSSION
Taken together, the results of this study suggest that the strength of the protein homeostasis system that
responds to protein aggregation is a central element in determining the vulnerability of cells and tissues to
protein misfolding diseases. Our analysis shows that brain tissues are less effective than other body tissues
in dealing with the problems posed by protein aggregation. The protection factor s serves as an effective
measure of the vulnerability of different tissue types to protein aggregation, as it decreases progressively
from body tissues to resistant brain tissues to highly vulnerable brain tissues (Figures 1 and 2). It also pro-
vides insights into the molecular origins of Alzheimer’s disease, as neurons have the lowest value of s of all
the types of cells found in the central nervous system (Figure 3).
As the human brain experienced a rapid cortical reorganization during the course of recent evolution from
non-human species, one may speculate that the expression levels of critical genes could also have
increased too rapidly for the simultaneous evolution of the regulatory components of the protein
A
B
Figure 4. Proteins in the Oxidative Phosphorylation Pathway Have a Weaker Protein Homeostasis Response to
Protein Aggregation in the Brain than in Other Tissues
(A) Average expression of the genes corresponding to the metastable subproteome (MS) within the KEGG oxidative
phosphorylation (OP) pathway (inset) and their associated PHC.
(B) Average expression of all genes corresponding to non-metastable proteins within the OP pathway and their
associated PHC. The value of s for these critical genes is lower (<1) throughout the body, not just in the brain, and the
difference in the values of s between the body brain tissues is more pronounced for the genes encoding for metastable
proteins in the oxidative phosphorylation pathway. The subunits in pink in the schematic show the location of the
metastable genes within the oxidative phosphorylation pathway. The colour code is the same as in Figure 1.
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homeostasis system. In this view, when faced with the challenges posed by aggregation-prone proteins,
brain tissues are more likely to suffer from protein aggregation diseases.
In conclusion, our results indicate that the specific vulnerability of certain brain tissues to protein aggrega-
tion is associated with their relative inability to regulate this process already in the healthy state. Further-
more, we have also provided evidence that this inability is characteristic of neurons, which are therefore
observed to be the earliest affected by protein misfolding diseases, compared with other brain cell types.
These observations link the molecular origins of this neurodegenerative disease to the specific branch of
the protein homeostasis network that regulates the maintenance in their soluble state of the proteins that
are metastable against aggregation.
Limitations of the Study
In this study, we investigated the cell- and tissue-specific capacity of the protein homeostasis system to
respond to the pressure caused by the overall expression of aggregation-prone proteins. Although useful
insights can be derived from a transcriptome-level analysis, as we have done here, a proteome-level anal-
ysis will in future studies provide more stringent conclusions.
It is possible that specific genetic traits of different individuals could influence the results in the transcrip-
tional analysis carried out using just six control healthy brains from the Allen Brain Atlas. We also note that
the transcriptional analyses of brain and non-brain tissues were carried out on different datasets, again
leaving open the possibility that genetic traits of specific individuals could influence the results.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100934.
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Transparent Methods 
 
 
Dataset Acquisition 
 
Healthy brain tissues. Microarray data for healthy brain tissues were acquired from the Allen Brain 
Atlas (Hawrylycz et al., 2012). Gene expression data for 6 healthy human brains were available, 
across 900 different tissues. Data were scaled and normalised using the ‘scale’ function of the 
Weighted Gene Correlation Network (WGCNA) package (Langfelder and Horvath, 2008). As the 
Allan Brain Atlas uses multiple probes for each genes, the ‘collapseRows’ function of WGCNA 
package was used to get a single expression value for each gene across all samples. The expression 
values for each gene was then averaged across all six brains to arrive at the final expression value 
associated with each gene (Kundra et al., 2017). 
 
Tissue specific data. We obtained tissue specific data across various human tissues from a previously 
published dataset (Su et al., 2004). Certain cancerous tissues and cell lines were removed from the 
analysis as our aim was to study the expression levels in a healthy state, leaving 77 tissues for the 
study (Table S1). From these, 27 were characterised as neural tissues and 50 body tissues (Table S1). 
For the Braak and Non-Braak analysis, brain regions (from the 27 brain tissues) were assigned to 
either Braak or Non-Braak (Freer et al., 2016). Briefly, brain regions in the Allen Brain Atlas were 
matched with the closest regions mentioned in the original paper (Braak and Braak, 1991). 7 tissues 
were found to correspond to different Braak stages (Table S1) 
 
Cell type specific data. Single-cell RNAseq data for 4 different cell types found in the brain were 
obtained from a published dataset (Darmanis et al., 2015). Data were scaled and normalised in R.   
 
Coexpression network construction 
We used the data obtained from the Allen Brain Atlas to construct a coexpression network for the 
genes corresponding to the metastable subproteome associated with Alzheimer’s disease (MS) 
(Kundra et al., 2017) and the genes associated with the protein homeostasis system to get the protein 
	 2	
homeostasis complement (PHC) of the MS. WGCNA was used to construct the coexpression network 
(Kundra et al., 2017). Briefly, WGCNA is a clustering algorithm based on hierarchical clustering but 
which uses ‘soft thresholding’ and the concept of topological overlap or shared neighbours to identify 
clusters of coexpressed genes. The soft thresholding method assigns a weight to each pair of 
interacting genes and uses such weight along with the topological overlap to identify modules of 
coexpressed genes in the expression data.  
 
Calculation of the protection factor s 
Since our aim was to study the balance between the expression level of aggregation prone proteins and 
components associated with their regulation, we defined a protection factor, s, as the slope of the best-
fit line for the relative expression of the MS and its PHC across different tissue or cell types. A line 
was fitted based on linear regression between the expression of MS and the PHC. The protection 
factor is a measure of the strength of the balance between the MS and its PHC.  
 
Statistical testing 
To evaluate the significance of our results, we used random sets of genes corresponding in number to 
the MS and PHC and calculated the s for them. We then calculated the difference in s between the 
body and brain tissues (Δs). We repeated these 1000 times to have a frequency distribution of Δs 
values for random sets of genes. The Δs for our genes of interest is 0.25, which is more than two SD 
away from the random sets of genes (Figure S1). Thus, our s values are highly robust and significant. 
The statistical testing was performed using the Scipy module in Python. The comparison of different 
‘s’ values was done using a two-tailed t test with a value of a of 0.001. 
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Tissue Classification (1) Classification (2) 
Adipocyte Body - 
Adrenal cortex Body - 
Adrenal gland Body - 
Appendix Body - 
Atrioventricular Node Body - 
BDCA4+DentriticCells Body - 
Bone marrow Body - 
Bronchial Epithelial Cells Body - 
CD105+_Endothelial Body - 
CD14+_Monocytes Body - 
CD19+_BCells(neg._sel.) Body - 
CD33+_Myeloid Body - 
CD34+ Body - 
CD4+_Tcells Body - 
CD56+_NKCells Body - 
CD71+_EarlyErythroid Body - 
CD8+_Tcells Body - 
Cardiac Myocytes Body - 
Fetal Thyroid Body - 
Fetal liver Body - 
Fetal lung Body - 
Heart Body - 
Kidney Body - 
Liver Body - 
Lung Body - 
Lymphnode Body - 
Ovary Body - 
Pancreas Body - 
Pancreatic Islet Body - 
Placenta Body - 
Prostate Body - 
Salivary gland Body - 
Skeletal muscle Body - 
Skin Body - 
Smooth muscle Body - 
Testis Body - 
Testis Germ Cell Body - 
Testis Intersitial Body - 
Testis Leydig Cell Body - 
Testis Seminiferous Tubule Body - 
Thymus Body - 
Thyroid Body - 
Tongue Body - 
Tonsil Body - 
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Trachea Body - 
Uterus Body - 
Uterus Corpus Body - 
Whole Blood Body - 
colon Body - 
Small intestine Body - 
Amygdala Brain Braak 
Caudate nucleus Brain Non Braak 
Cerebellum Brain Non Braak 
Cerebellum peduncles Brain Non Braak 
Ciliary ganglion Brain Non Braak 
Cingulate cortex Brain Braak 
Dorsal root ganglion Brain Non Braak 
Fetal brain Brain Non Braak 
Globus pallidus Brain Non Braak 
Hypothalamus Brain Braak 
Medulla oblongata Brain Non Braak 
Occipital lobe Brain Braak 
Olfactory bulb Brain Non Braak 
Parietal lobe Brain Non Braak 
Pons Brain Non Braak 
Prefrontal cortex Brain Braak 
Spinalcord Brain Non Braak 
Subthalamic nucleus Brain Non Braak 
Superior cervical ganglion Brain Non Braak 
Temporal lobe Brain Braak 
Thalamus Brain Braak 
Trigeminal ganglion Brain Non Braak 
Whole brain Brain Non Braak 
Pineal day Brain Non Braak 
Pineal night Brain Non Braak 
Pituitary Brain Non Braak 
retina Brain Non Braak 
 
 
Table S1. List of the 77 different tissues used in the analysis. The Braak classification (Braak 
and Braak, 1991) is reported for brain tissues, related to Figure 1. 
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Figure S1. Histogram showing Δs (difference in s for body tissues and brain tissues) for 1000 
random sets of genes, related to Figure 1. The Δs for our genes of interest (genes that are 
supersaturated and downregulated only in Alzheimer’s disease, and the associated PHC) is 0.25 
(shown by red arrow). 
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Figure S2. Neurons have a lower value of protection factor s compared to other non-neuronal 
cell types, related to Figure 3.  *** p<0.001, see Methods. 
 
 
 
 
